Edgewise Therapeutics Issues Equity Grants to New Staff
Boulder-based Edgewise Therapeutics issued stock options and restricted stock units to four new non-executive employees on August 31, 2026. The grants, totaling 21,000 options and 10,501 restricted units, serve as material inducements for these hires to join the clinical-stage biopharmaceutical firm under the company’s 2024 equity incentive plan.
The stock options carry an exercise price of $41.77 per share, matching the closing price of the company's common stock on the grant date. Vesting for these options begins with a 25% cliff on the one-year anniversary of the employee's start date, followed by monthly accruals of 1/48th of the total shares over the subsequent three years of service.
Restricted stock unit awards follow a different timeline, vesting in four equal annual installments on each anniversary of the grant date. These equity packages were authorized under Nasdaq Listing Rule 5635(c)(4), which allows for the issuance of securities to new hires as a condition of their employment agreement.
Comments (0)
No comments yet. Be the first!